Amortization expense was approximately $46 for both the three months ended March 31, 2018 and March 31, 2017.
During the third quarter of 2017, we revised the June 2016 Plan.
Generally, these RSUs vest over a three-year period.
Our effective income tax rate was 24.5% and 30.6% in the first quarters of 2018 and 2017, respectively.
The decrease in the effective tax rate for the three months ended March 31, 2018, compared with the same period in 2017, was primarily attributed to the impact of the Tax Cuts and Jobs Act (the "Act"), which reduced the U.S. federal corporate income tax rate from 35 percent to 21 percent effective January 1, 2018.
No common stock repurchases were made during the three months ended March 31, 2018.
In June 2016, we announced plans to restructure operations by phasing out production at our Elkhart facility by the end of 2018 and transitioning it into a research and development center supporting our global operations ("June 2016 Plan").
For these computations, we have recorded an estimate in our effective tax rate for the three-months ended March 31, 2018.
Transaction gains for the three months ended March 31, 2018 and March 31, 2017 were $1,996 and $395, respectively, which have been included in other income (expense) in the Condensed Consolidated Statement of Earnings.
During the three months period ended March 31, 2018, we recognized revenues of $131 that were included in contract liabilities at the beginning of the period.
The increase in contract liabilities during the three months ended March 31, 2018 is primarily due to net increases in estimated future discounts and price concessions, offset by net settlements of products sold with rights of return.Changes in foreign exchange rates increased sales by $2,751 year-over-year due to the U.S. Dollar depreciating compared to the Euro and Chinese Renminbi and relating mostly to sales of automotive products.
Gross margin as a percent of sales was 33.9% in the first quarter of 2018 compared to 34.2% in the first quarter of 2017.
Item 2.
Sales were $113,530 in the first quarter of 2018, an increase of $13,376 or 13.4% from the first quarter of 2017.
Based upon our latest assessment, we determined that our goodwill was not impaired as of October 1, 2017.
Research and development expenses were $6,507 or 5.7% of sales in the first quarter of 2018 compared to $6,003 or 6.0% of sales in the comparable quarter of 2017.
The charges were mainly for building and equipment relocation, severance, and travel costs related to the restructuring of certain operations as part of the 2016 Restructuring Plan.